Anne de Brugerolle

PROFILE General Manager R&D General management of an R&D Department, Management of a Business Unit, Business Development R&D in pharmaceutical, medical devices, cosmetics and biotechnologies industries Expert in Dermatology, Immunology, Inflammation and biotechnologies COMPETENCIES - Operational management of R&D teams - Identification of innovative and value added opportunities - Launch of new pharmaceutical, medical devices and cosmetic products - Scientific and strategic analysis of portfolios and targets in Dermatology, Immunology, Transplantation and Inflammation, radar screening and competitive intelligence for detecting innovative and disruptive technologies - Market share expansion and consolidation towards emerging markets in Europe, USA and Asia (Japan, India) PROFESSIONAL EXPERIENCES Director of a Research Center, L’Oreal, Paris, France — 2006-2011 General manager of SkinEthic/L’Oréal- Member of the Global R&D Direction- General Management of a Research Department and SkinEthic SA, an affiliated company of L’Oréal’s group (dedicated to the human tissue 3D reconstruction of human skin, cornea and mucosa) Executive Director, Novartis Pharma, Basel, Switzerland — 2000-2006- Management of International and multidisciplinary teams at Corporate and Global Early Development levels- Scientific and strategic analysis of portfolios and company profiles from pharmaceutical and biotech companies in particular in Dermatology, Immunology, Inflammation and Transplantation within the frame of merger and acquisition (detection of Alcon, ophtalmic specialties in USA recently acquired by Novartis Pharma) and comptetitive intelligence (genomics, biosimulation, biotechnologies) in Preclinical safety and Early Development (from Research to Phase II) - Strategic analysis of selected partnerships with CROs for Early Development in emerging markets (India) - Integration of co-development Alliances for example Apligraf with Organogenesis, Boston, USA Portfolio manager, Novartis Pharma, Basel, Switzerland — 1993-2000- Management of International Portfolios of Projects in Preclinical Safety- Implementation and management of technological plateforms in Immunotoxicology (Local Lymph Node Assay in mice in vivo and in vitro human reconstructed skin models co-cultured with immune cells) and Drug Delivery Systems (transdermal, nasal and bronchial in vitro reconstructed human tissues or cultured cells) for preclinical safety screening EDUCATION INSEAD, Fontainebleau, France — Executive MBA, 2000 University Hospital, Zûrich, Switzerland; Research Associate, 1990-1992UC Davis, San Francisco, USA; Research fellow, 1989-1990 University Claude Bernard, Lyon, France — Ph.D. 1989 Hospices Civils de Lyon, Lyon, France — 1985-1989 University Claude Bernard, Lyon, France — Pharm.D. 1987 LANGUAGES English: fluent German: notions Spanish: learner